** Shares of biotech firm Trinity Biotech TRIB.O rise ~56% to $1.18
** TRIB says its next-generation continuous glucose monitoring (CGM) system showed superior signal quality, enhanced reliability and breakthrough accuracy compared to previous sensors
** CGM is for people with Type 1 and Type 2 diabetes aged 18 years and older
** Co plans to file for regulatory approval in EU in 2025 and in U.S. in 2026
** TRIB fell 60% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))